- by Rob Camp
- April 4 2018
- IVD
- molecular diagnostics
The CRISPR Diagnostic Toolkit Gets Handier
A new platform based on the gene editing technique is unveiled, and an old-but-still-pretty-new method gets an update. Plus, a CRISPR-related retraction.
- by Bruce Carlson
- August 18 2017
- molecular diagnostics
- molecular POC
Molecular POC Makes Strides
Six companies to watch in the development of rapid and small footprint DNA testing near patient.
- by Bruce Carlson
- July 19 2017
- bioinformatics
- blood screening
- Healthcare & Biotechnology
- molecular diagnostics
5 Trends to Watch in the Liquid Biopsy Market
The liquid biopsy market is experiencing four trends driving growth, and one trend that should be watched as a limited trend.
- by Emil Salazar
- April 13 2017
- cancer diagnostics
- molecular diagnostics
Qiagen Adds to Leading Molecular Cancer Menu with FDA-Cleared JAK2 Test Kit
The U.S. Food and Drug Administration (FDA) recently approved Qiagen’s ipsogen JAK2 RGQ PCR Kit for detection of the V617F mutation on the JAK2 gene associated with the myeloproliferative disorder polycythemia vera. The cancer test kit assists patient evaluation for the particular form of leukemia and is routinely tested in myeloproliferative neoplasms (MPNs) negative for mutation in the BCR-ABL gene. Kit availability for JAK2 testing will make the test more widely available to health systems for the implementation of personalized medicine for leukemia patients.
- by Emil Salazar
- April 6 2017
- infectious disease diagnostics
- molecular diagnostics
- molecular POC
Molecular Diagnostics Faces Competition for Future Point of Care Testing in Developing World
The sensitivity and specificity of nucleic acid analytes provide molecular diagnostics key advantages in clinical practice, particularly in critical health situations. Nucleic acid amplification (NAATs) or molecular tests are now open to routine and distributed use in healthcare thanks to advancements in microfluidics and molecular reagents. As molecular diagnostics enter point-of-care (POC) settings, cost becomes a key issue in comparison to predominantly used and cheaply performed rapid immunoassays.
- by Emil Salazar
- March 28 2017
- autism diagnostics
- molecular diagnostics
Recent Autism Test Studies Add to Promising, Yet Inconclusive Research into Psychiatric Diagnostics
In two recent studies, in vitro diagnostic (IVD) assays have been investigated that incorporate biomarkers for environmental factors and dysfunctional cellular pathways associated with autism spectrum disorders (ASDs). The accuracy of these oftentimes complex lab tests for ASD has improved with extensive genomic research into the disorder among large groups of ASD-affected families and between ASD and neurotypical siblings. While the clinical utility of a diagnostic lab test for ASD or ASD predisposition would be unquestionably high (particularly in young children and infants), additional research and assay validation across ASD populations is necessary to secure widespread clinical acceptance and payer coverage.
- by Bruce Carlson
- March 3 2017
- molecular diagnostics
Test Guidelines Positive News for Cancer MDx Market
New guidelines on the use of biomarker-based tests for colorectal cancer are welcome news for test developers. We cover molecular-based cancer assays in our new report, The World Market for Molecular Diagnostics, 7th Edition.
- by Emil Salazar
- January 27 2017
- hepatitis
- infectious disease diagnostics
- molecular diagnostics
New Therapies, Risk Factors Drive Hepatitis C Diagnostics
This blog post discusses findings from Kalorama Information’s just-published market research report, The World Market for Molecular Diagnostics, 7th Edition (Infectious Disease, Cancer, NAT Blood Screening, Transplantation, Histology/Cytology, Inherited Diseases).
Clinical molecular diagnostics does not lack in targets. Dynamic expansion markets in point-of-care testing and cancer have headlined assay development efforts in recent years, but they are not the only major opportunities in molecular diagnostics.
- by Emil Salazar
- January 13 2017
- molecular diagnostics
Advanced Staining (IHC, ISH) in Clinical Diagnostics’ Genomic Age
The least glamorous and most labor intensive segment of clinical molecular diagnostic testing, histology and advanced stains such as in situ hybridization (ISH) and immunohistochemistry (IHC) endure even as their markets shift to other lab workflows and emerging IVD technologies.
- by Emil Salazar
- December 13 2016
- cancer diagnostics
- China
- clinical sequencing
- molecular diagnostics
- next generation sequencing
Chinese Market Comes to the Fore in Cancer Diagnostics
In 2016, China is a clear market development priority for the IVD industry in the areas of cancer screening tests, companion diagnostics, and sequencing-based cancer assays.
